Literature DB >> 16977633

Prognostic value of neutrophils and NK cells in bronchoalveolar lavage of sarcoidosis.

Pablo Tutor-Ureta1, María J Citores, Raquel Castejón, Susana Mellor-Pita, Miguel Yebra-Bango, Yolanda Romero, Juan A Vargas.   

Abstract

BACKGROUND: Not all the patients with sarcoidosis need pharmacological therapy, and the decision to start therapy is based mainly on clinical conditions. The aim of this study was to evaluate the prognostic value of the leukocyte and lymphocyte subpopulations in the bronchoalveolar lavage fluid from these patients.
METHODS: Thirty-three nonsmoking patients with sarcoidosis were included and classified based on the presence of Löfgren's syndrome (n = 11), the radiological stage (12 at Stage I, 17 at Stage II, and 4 at Stage III), and their follow-up. Differential leukocyte subsets and the lymphocyte subpopulations were determined by flow cytometry.
RESULTS: The percentage of neutrophils was lower in patients with Löfgren's syndrome (P = 0.038) and in patients at Stage I (P = 0.002). Patients with a poor outcome had a higher percentage of neutrophils (P = 0.004) and NK cells (P = 0.023) than those with a stable disease. Finally, a higher percentage of NK cells was found in those patients who needed a steroid treatment (P = 0.012).
CONCLUSIONS: Increased percentages of neutrophils and NK cells in the bronchoalveolar lavage fluid from patients with sarcoidosis are associated with a poor outcome and a higher probability to need steroids treatment. The percentage of neutrophils was also lower in patients with Löfgren's syndrome. Copyright 2006 International Society for Analytical Cytology.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16977633     DOI: 10.1002/cyto.b.20120

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN: 1552-4949            Impact factor:   3.058


  13 in total

1.  Induction of Pulmonary Granuloma Formation by Propionibacterium acnes Is Regulated by MyD88 and Nox2.

Authors:  Jessica L Werner; Sylvia G Escolero; Jeff T Hewlett; Tim N Mak; Brian P Williams; Yoshinobu Eishi; Gabriel Núñez
Journal:  Am J Respir Cell Mol Biol       Date:  2017-01       Impact factor: 6.914

2.  MRP14 is elevated in the bronchoalveolar lavage fluid of fibrosing interstitial lung diseases.

Authors:  N M Korthagen; M M Nagtegaal; C H M van Moorsel; K M Kazemier; J M M van den Bosch; J C Grutters
Journal:  Clin Exp Immunol       Date:  2010-06-09       Impact factor: 4.330

3.  Human neutrophils switch to an activated phenotype after homing to the lung irrespective of inflammatory disease.

Authors:  E Fortunati; K M Kazemier; J C Grutters; L Koenderman; van J M M Van den Bosch
Journal:  Clin Exp Immunol       Date:  2008-12-09       Impact factor: 4.330

4.  Protein levels of CC chemokine ligand (CCL)15, CCL16 and macrophage stimulating protein in patients with sarcoidosis.

Authors:  A Arakelyan; E Kriegova; Z Kubistova; F Mrazek; M Kverka; R M du Bois; V Kolek; M Petrek
Journal:  Clin Exp Immunol       Date:  2009-03       Impact factor: 4.330

5.  Use of discriminant analysis in assessing pulmonary function worsening in patients with sarcoidosis by a panel of inflammatory biomarkers.

Authors:  Gregorino Paone; Alvaro Leone; Sandro Batzella; Vittoria Conti; Francesco Belli; Laura De Marchis; Alice Mannocci; Giovanni Schmid; Claudio Terzano
Journal:  Inflamm Res       Date:  2012-12-23       Impact factor: 4.575

Review 6.  Granuloma formation in pulmonary sarcoidosis.

Authors:  Caroline E Broos; Menno van Nimwegen; Henk C Hoogsteden; Rudi W Hendriks; Mirjam Kool; Bernt van den Blink
Journal:  Front Immunol       Date:  2013-12-10       Impact factor: 7.561

Review 7.  NK Cells in the Human Lungs.

Authors:  Baptiste Hervier; Jules Russick; Isabelle Cremer; Vincent Vieillard
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 7.561

Review 8.  Biomarkers in the Diagnosis and Prognosis of Sarcoidosis: Current Use and Future Prospects.

Authors:  Raisa Kraaijvanger; Montse Janssen Bonás; Adriane D M Vorselaars; Marcel Veltkamp
Journal:  Front Immunol       Date:  2020-07-14       Impact factor: 7.561

9.  BALF and BLOOD NK- cells in different stages of pulmonary sarcoidosis.

Authors:  Katerina Manika; Kalliopi Domvri; George Kyriazis; Theodoros Kontakiotis; Despina Papakosta
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2022-01-13       Impact factor: 0.670

10.  Effects of infliximab on lung and circulating natural killer cells, CD56+ T cells and B cells in sarcoidosis.

Authors:  Susanna Kullberg; Natalia V Rivera; Johan Grunewald; Anders Eklund
Journal:  BMJ Open Respir Res       Date:  2021-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.